WuXi Biologics facility secures FDA approval for autoimmune drug
July 10, 2026 | 11:42
WuXi Biologics' MFG8 drug substance manufacturing facility in Hebei passed the FDA's Pre-License Inspection, advancing commercial supply of a potential blockbuster autoimmune therapy, the Hong Kong-listed CRDMO announced.
Mobile Version